Influence of propranolol on supraventricular tachycardia early after coronary artery revascularization. A randomized trial

M. F. Ivey, T. D. Ivey, W. W. Bailey, Donald Williams, E. A. Hessel, D. W. Miller

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

A total of 116 patients undergoing coronary revascularization were randomized preoperatively in a double-blind manner to receive 80 mg daily of propranolol or placebo in the postoperative period. Preoperatively, all patients had been receiving at least 80 mg of propranolol a day to the time of the operation. In addition, all patients had a left-ventricular ejection fraction of 0.4 or more, no history of supraventricular tachyarrhythmia (SVT), and no need of digitalis preparations or other antiarrhythmic drugs. All patients were monitored for 5 days and propranolol or placebo was started 24 hours postoperatively. SVT was documented with biatrial electrograms in all cases. Study groups were similar in postoperative creatine kinase MB levels and postoperative weight gain, but the placebo group tended to be older and have more grafts per patient. Seven patients randomized were dropped from the study, two with perioperative infarction, four with persistent ventricular arrhythmias necessitating quinidine or procainamide, and one with persistent postoperative hypotension (placebo). There were no significant differences in the incidence of postoperative SVT in these two groups: 13.2% in the propranolol group and 16.1% in the placebo group. We conclude that 80 mg daily of propranolol given postoperatively to patients undergoing coronary revascularization does not effectively reduce the incidence of SVT.

Original languageEnglish
Pages (from-to)214-218
Number of pages5
JournalJournal of Thoracic and Cardiovascular Surgery
Volume85
Issue number2
StatePublished - Jul 7 1983
Externally publishedYes

Fingerprint

Supraventricular Tachycardia
Propranolol
Coronary Vessels
Tachycardia
Placebos
Procainamide
MB Form Creatine Kinase
Quinidine
Digitalis
Anti-Arrhythmia Agents
Incidence
Postoperative Period
Stroke Volume
Hypotension
Infarction
Weight Gain
Cardiac Arrhythmias
Transplants

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Ivey, M. F., Ivey, T. D., Bailey, W. W., Williams, D., Hessel, E. A., & Miller, D. W. (1983). Influence of propranolol on supraventricular tachycardia early after coronary artery revascularization. A randomized trial. Journal of Thoracic and Cardiovascular Surgery, 85(2), 214-218.

Influence of propranolol on supraventricular tachycardia early after coronary artery revascularization. A randomized trial. / Ivey, M. F.; Ivey, T. D.; Bailey, W. W.; Williams, Donald; Hessel, E. A.; Miller, D. W.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 85, No. 2, 07.07.1983, p. 214-218.

Research output: Contribution to journalArticle

Ivey, M. F. ; Ivey, T. D. ; Bailey, W. W. ; Williams, Donald ; Hessel, E. A. ; Miller, D. W. / Influence of propranolol on supraventricular tachycardia early after coronary artery revascularization. A randomized trial. In: Journal of Thoracic and Cardiovascular Surgery. 1983 ; Vol. 85, No. 2. pp. 214-218.
@article{1b283f78af554418ba37c9d269707e1e,
title = "Influence of propranolol on supraventricular tachycardia early after coronary artery revascularization. A randomized trial",
abstract = "A total of 116 patients undergoing coronary revascularization were randomized preoperatively in a double-blind manner to receive 80 mg daily of propranolol or placebo in the postoperative period. Preoperatively, all patients had been receiving at least 80 mg of propranolol a day to the time of the operation. In addition, all patients had a left-ventricular ejection fraction of 0.4 or more, no history of supraventricular tachyarrhythmia (SVT), and no need of digitalis preparations or other antiarrhythmic drugs. All patients were monitored for 5 days and propranolol or placebo was started 24 hours postoperatively. SVT was documented with biatrial electrograms in all cases. Study groups were similar in postoperative creatine kinase MB levels and postoperative weight gain, but the placebo group tended to be older and have more grafts per patient. Seven patients randomized were dropped from the study, two with perioperative infarction, four with persistent ventricular arrhythmias necessitating quinidine or procainamide, and one with persistent postoperative hypotension (placebo). There were no significant differences in the incidence of postoperative SVT in these two groups: 13.2{\%} in the propranolol group and 16.1{\%} in the placebo group. We conclude that 80 mg daily of propranolol given postoperatively to patients undergoing coronary revascularization does not effectively reduce the incidence of SVT.",
author = "Ivey, {M. F.} and Ivey, {T. D.} and Bailey, {W. W.} and Donald Williams and Hessel, {E. A.} and Miller, {D. W.}",
year = "1983",
month = "7",
day = "7",
language = "English",
volume = "85",
pages = "214--218",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Influence of propranolol on supraventricular tachycardia early after coronary artery revascularization. A randomized trial

AU - Ivey, M. F.

AU - Ivey, T. D.

AU - Bailey, W. W.

AU - Williams, Donald

AU - Hessel, E. A.

AU - Miller, D. W.

PY - 1983/7/7

Y1 - 1983/7/7

N2 - A total of 116 patients undergoing coronary revascularization were randomized preoperatively in a double-blind manner to receive 80 mg daily of propranolol or placebo in the postoperative period. Preoperatively, all patients had been receiving at least 80 mg of propranolol a day to the time of the operation. In addition, all patients had a left-ventricular ejection fraction of 0.4 or more, no history of supraventricular tachyarrhythmia (SVT), and no need of digitalis preparations or other antiarrhythmic drugs. All patients were monitored for 5 days and propranolol or placebo was started 24 hours postoperatively. SVT was documented with biatrial electrograms in all cases. Study groups were similar in postoperative creatine kinase MB levels and postoperative weight gain, but the placebo group tended to be older and have more grafts per patient. Seven patients randomized were dropped from the study, two with perioperative infarction, four with persistent ventricular arrhythmias necessitating quinidine or procainamide, and one with persistent postoperative hypotension (placebo). There were no significant differences in the incidence of postoperative SVT in these two groups: 13.2% in the propranolol group and 16.1% in the placebo group. We conclude that 80 mg daily of propranolol given postoperatively to patients undergoing coronary revascularization does not effectively reduce the incidence of SVT.

AB - A total of 116 patients undergoing coronary revascularization were randomized preoperatively in a double-blind manner to receive 80 mg daily of propranolol or placebo in the postoperative period. Preoperatively, all patients had been receiving at least 80 mg of propranolol a day to the time of the operation. In addition, all patients had a left-ventricular ejection fraction of 0.4 or more, no history of supraventricular tachyarrhythmia (SVT), and no need of digitalis preparations or other antiarrhythmic drugs. All patients were monitored for 5 days and propranolol or placebo was started 24 hours postoperatively. SVT was documented with biatrial electrograms in all cases. Study groups were similar in postoperative creatine kinase MB levels and postoperative weight gain, but the placebo group tended to be older and have more grafts per patient. Seven patients randomized were dropped from the study, two with perioperative infarction, four with persistent ventricular arrhythmias necessitating quinidine or procainamide, and one with persistent postoperative hypotension (placebo). There were no significant differences in the incidence of postoperative SVT in these two groups: 13.2% in the propranolol group and 16.1% in the placebo group. We conclude that 80 mg daily of propranolol given postoperatively to patients undergoing coronary revascularization does not effectively reduce the incidence of SVT.

UR - http://www.scopus.com/inward/record.url?scp=0020596666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020596666&partnerID=8YFLogxK

M3 - Article

C2 - 6337306

AN - SCOPUS:0020596666

VL - 85

SP - 214

EP - 218

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 2

ER -